Takeda Pharmaceutical Company Limited (TAK) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Takeda Pharmaceutical Company Limited  (NYSE: TAK)


Takeda Pharmaceutical Limited's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Takeda Pharmaceutical Limited's ROI in the first quarter of 2026?
Takeda Pharmaceutical Company Limited achieved a return on average invested assets (ROI) of 3.12 % in its first quarter of 2026, this is above TAK's average return on investment of 2.27%.
Takeda Pharmaceutical Company Limiteds investments during the 12 months ending in the first quarter of 2026 are valued at $72 billion

ROI has improved compared to 2.41% in the fourth quarter of 2025, due to net income growth.

Within the Healthcare sector 182 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from to 2249.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
I. Quarter		 (Mar 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Investment Change TTM 8.38 % -4.94 % -0.88 % -1.54 % 2.66 %
Y / Y Net Income Change TTM 41.41 % -3.06 % 201.9 % 201.9 % -
Investment (TTM) in Millions 96,733 62,099 69,144 62,099 64,199
Return On Investment (TTM) 3.12 % 2.41 % 2.79 % 2.83 % 2.39 %
TAK's Overall Ranking # 2249 # # # #
Seq. Investment Change TTM 12.63 % -2.66 % 1.53 % -2.63 % -1.2 %
Seq. Net Income Change TTM 45.87 % -16.11 % 0 % 15.56 % 0 %
Net Income (TTM) in Millions 2,260 1,549 1,847 1,847 1,598

TAK Company Profile >> Back to TAK Roi Comparisons >> See Annual TAK Return On Investment



Return On Investment TAK's Ranking
Within: No.
Industry # 60
Sector # 183
Overall # 2249

Return On Investment Statistics
High Average Low
4.9 %
2.27 %
0.8 %
(Mar 31 2021)   (Mar 31 2020)







Financial Statements
Takeda Pharmaceutical Limited's I. Quarter Investments $ 96,733 Millions TAK's Balance sheet
Takeda Pharmaceutical Limited's I. Quarter Income $ 711 Millions Quarterly TAK's Income Statement
TAK's Income by Division See TAK's Income by Division


TAK Annual Return On Investment (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021
Total Investments in Millions 64,199 67,462 69,177 68,515 70,686
Y / Y Investment Growth -4.84 % -2.48 % 0.97 % -3.07 % 38.82 %
Net Income in Millions 710 999 2,345 2,050 3,549
Y / Y Net Income Growth -28.92 % -57.41 % 14.41 % -42.23 % 770.94 %
Annual Return On Investment 1.11 % 1.48 % 3.39 % 2.99 % 5.02 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 1.11 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TAK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TAK's Competitors
Subscribers only: Roi for Takeda Pharmaceutical Limited's Suppliers
Subscribers only: Return On Investment for TAK's Customers

Other Ratios
TAK's Roa TAK's Inventory Turnover Ratio TAK's Growth Rates TAK's Dividend Statistics
TAK's Profitability Ratios TAK's Asset Turnover Ratio TAK's Dividend Growth
TAK's Roe TAK's Valuation Ratios TAK's Financial Strength Ratios TAK's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Edwards Lifesciences Corporation  8.39 %
Veracyte Inc   8.15 %
Phibro Animal Health Corporation  8.11 %
Brightspring Health Services Inc   8.05 %
Quest Diagnostics Inc  8.05 %
Addus Homecare Corp  7.98 %
Corcept Therapeutics Inc  7.96 %
Amneal Pharmaceuticals Inc   7.91 %
Concentra Group Holdings Parent Inc   7.89 %
Bio techne Corp  7.61 %
Pacific Health Care Organization Inc  7.42 %
Davita Inc   6.92 %
Kewaunee Scientific Corporation  6.58 %
Medtronic Plc  6.46 %
Siga Technologies Inc  6.45 %
Labcorp Holdings Inc   6.11 %
Pacs Group Inc   5.86 %
Merit Medical Systems Inc  5.80 %
Ensign Group Inc  5.75 %
Nrc Health  5.72 %
IMPACT BIOMEDICAL INC.  5.68 %
Vericel Corporation  5.58 %
Royalty Pharma Plc  5.45 %
Amphastar Pharmaceuticals Inc   5.33 %
Sotera Health Company  5.21 %
The Cooper Companies Inc   5.09 %
Henry Schein Inc   5.06 %
Cadre Holdings inc   4.92 %
Haemonetics Corporation  4.91 %
The Pennant Group Inc   4.62 %

Date modified: 2026-10-15T05:23:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.